Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)

被引：0
|
作者：
Ip, H. N. N. [1 ]
Hwang, I. [2 ]
Kang, J. [2 ]
Kim, K-P. [2 ]
Jeong, J. H. [2 ]
Chang, H-M. [2 ]
Ryoo, B-Y. [2 ]
Yoo, C. [2 ]
机构：
[1] Chinese Univ Hong Kong, Med, Hong Kong, Peoples R China
[2] Asan Med Ctr, Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
193P
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [21] Analysis of early tumor shrinkage and depth of response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or gemcitabine plus nab-paclitaxel
    Vivaldi, C.
    Cappelli, C.
    Donati, F.
    Fornaro, L.
    Musettini, G.
    Pasquini, G.
    Pecora, I.
    Catanese, S.
    Lencioni, M.
    Salani, F.
    Boraschi, P.
    Falcone, A.
    Vasile, E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
    Hatashima, Alycia
    Arango, Matthew J.
    Reardon, Joshua
    Freeman, Tracelyn
    Williams, Terence
    McLaughlin, Eric M.
    Abushahin, Laith
    FUTURE ONCOLOGY, 2022, 18 (20) : 2521 - 2532
  • [23] Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX
    Kim, George P.
    Parisi, Monika F.
    Patel, Manish B.
    Pelletier, Corey L.
    Belk, Kathy W.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (05) : 559 - 565
  • [24] Sindilimab combined with nab-paclitaxel plus gemcitabine as first-line treatment for patients with advanced pancreatic cancer.
    Zhu, Huayun
    Sun, Xiaofeng
    Pan, Xuan
    Wu, Pingping
    Chen, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Angelica Petrillo
    Annalisa Pappalardo
    Luca Pompella
    Giuseppe Tirino
    Filomena Calabrese
    Maria Maddalena Laterza
    Marianna Caterino
    Anna Ventriglia
    Michele Orditura
    Giovanni Conzo
    Carlo Molino
    Fortunato Ciardiello
    Maria Biglietto
    Ferdinando De Vita
    Medical Oncology, 2019, 36
  • [26] The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
    Prejac, Juraj
    Hamzic, Dora Tomek
    Librenjak, Niksa
    Gorsic, Irma
    Kekez, Domina
    Plestina, Stjepko
    MEDICINE, 2022, 101 (39) : E30566
  • [27] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Petrillo, Angelica
    Pappalardo, Annalisa
    Pompella, Luca
    Tirino, Giuseppe
    Calabrese, Filomena
    Laterza, Maria Maddalena
    Caterino, Marianna
    Ventriglia, Anna
    Orditura, Michele
    Conzo, Giovanni
    Molino, Carlo
    Ciardiello, Fortunato
    Biglietto, Maria
    De Vita, Ferdinando
    MEDICAL ONCOLOGY, 2019, 36 (10)
  • [28] Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
    P. G. Corrie
    W. Qian
    B. Basu
    J. W. Valle
    S. Falk
    C. lwuji
    H. Wasan
    D. Palmer
    M. Scott-Brown
    J. Wadsley
    S. Arif
    J. Bridgewater
    D. Propper
    R. Gillmore
    A. Gopinathan
    R. Skells
    P. Bundi
    R. Brais
    K. Dalchau
    L. Bax
    A. Chhabra
    A. Machin
    A. Dayim
    K. McAdam
    S. Cummins
    L. Wall
    R. Ellis
    A. Anthoney
    J. Evans
    Y. T. Ma
    C. Isherwood
    A. Neesse
    D. Tuveson
    D. I. Jodrell
    British Journal of Cancer, 2020, 122 : 1760 - 1768
  • [29] Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
    Corrie, P. G.
    Qian, W.
    Basu, B.
    Valle, J. W.
    Falk, S.
    Iwuji, C.
    Wasan, H.
    Palmer, D.
    Scott-Brown, M.
    Wadsley, J.
    Arif, S.
    Bridgewater, J.
    Propper, D.
    Gillmore, R.
    Gopinathan, A.
    Skells, R.
    Bundi, P.
    Brais, R.
    Dalchau, K.
    Bax, L.
    Chhabra, A.
    Machin, A.
    Dayim, A.
    McAdam, K.
    Cummins, S.
    Wall, L.
    Ellis, R.
    Anthoney, A.
    Evans, J.
    Ma, Y. T.
    Isherwood, C.
    Neesse, A.
    Tuveson, D.
    Jodrell, D., I
    BRITISH JOURNAL OF CANCER, 2020, 122 (12) : 1760 - 1768
  • [30] Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer
    Kokkali, Stefania
    Tripodaki, Elli-Sophia
    Drizou, Maria
    Stefanou, Dimitra
    Magou, Elpida
    Zylis, Dimosthenis
    Kapiris, Matthaios
    Nasi, Despoina
    Georganta, Chara
    Ardavanis, Alexandros
    IN VIVO, 2018, 32 (03): : 653 - 657
12345